JAKNAT 5MG TABLET 10'S

Tell your doctor immediately if you start to have swelling of your face, lips, tongue, throat, arms, or legs or if you are having trouble swallowing or breathing. JAKNAT 5MG TABLET 10'S can temporarily lower the number of white blood cells in your blood, increasing the chance of getting an infection.

Increased cholesterol levels are one of the side effects of JAKNAT 5MG TABLET 10'S, your doctor may take regular blood tests to check for serious side effects.

No, JAKNAT 5MG TABLET 10'S does not cause depression. However, many people who have autoimmune conditions also have symptoms of depression. If you're having symptoms of depression, see your doctor right away.

Yes, blood clots are reported in patients using JAKNAT 5MG TABLET 10'S for a longer period. Inform your physician if you face any symptoms of a blood clot.

JAKNAT 5MG TABLET 10'S is a long-term treatment. Most people who benefit from this treatment will notice an improvement in the first 12 weeks of starting treatment.

There is no known interaction of JAKNAT 5MG TABLET 10'S with other drugs.

This medicine may interfere with vaccines, inform your physician about your vaccination history. This medicine may impair fertility; talk to your doctor before taking this medicine. Your doctor will regularly do lab tests to check whether the medicine is working. Do not breastfeed during the treatment with this medicine and for at least 36 hours after your last dose. This medicine may make you bleed, bruise, or get infections more easily. Take precautions to prevent illness and injury.

TOFACITINIB is molecule/combination used for making JAKNAT 5MG TABLET 10'S.

JAKNAT 5MG TABLET 10'S is prescribed for ailments/diseases/conditions related to Rheumatology.

JAKNAT 5MG TABLET 10'S is prescribed for ailments/diseases/conditions related to Orthopaedics.

Jaknat 5 contains a Janus kinase (JAK) inhibitor used to manage certain immune‑mediated and inflammatory conditions, such as some forms of arthritis, skin diseases, or other autoimmune disorders, depending on local regulatory approvals. The exact indication for you should be confirmed by your prescribing doctor, who will base the decision on your diagnosis, disease severity, and treatment history.

Jaknat 5 works by selectively inhibiting specific Janus kinase (JAK) enzymes that transmit signals from cytokines and growth factors involved in inflammation and immune responses. By dampening these signaling pathways, the medicine helps reduce abnormal immune activity, thereby decreasing inflammation, improving symptoms such as pain, swelling, or itching, and helping to control disease progression in certain conditions.

You should take Jaknat 5 exactly as prescribed by your doctor and as described in the patient information leaflet supplied with the medicine. Do not change the dose, frequency, or duration of treatment on your own. Swallow the tablet with water, with or without food, unless your doctor advises otherwise. If you miss a dose, follow your doctor’s instructions or the leaflet guidance rather than doubling the next dose. Never share this medicine with others, even if they have similar symptoms.

Jaknat 5, like other JAK inhibitors, can affect liver function in some patients. Elevations in liver enzymes may occur and are usually detected through routine blood tests. People with pre‑existing liver disease or a history of hepatitis require particular caution and closer monitoring. Your doctor will typically check liver function before starting treatment and at regular intervals thereafter. If you develop symptoms such as yellowing of the skin or eyes, dark urine, severe fatigue, or right‑upper abdominal pain, contact your doctor immediately. Dose adjustment, temporary interruption, or discontinuation may be needed if significant liver abnormalities occur.

Patients with kidney impairment may be able to take Jaknat 5, but they often require careful assessment and possible dose adjustment, depending on the severity of kidney dysfunction and local prescribing information. Reduced kidney function can influence how the drug is cleared from the body, which may increase the risk of side effects. Your doctor will usually evaluate kidney function with blood tests before starting therapy and periodically during treatment. People with severe kidney disease or on dialysis may need alternative options or very specific dosing recommendations, so they must follow specialist advice closely.

Use of Jaknat 5 during pregnancy is generally not recommended unless the potential benefit clearly outweighs the potential risk to the unborn baby, based on your doctor’s judgment and available local guidance. Data on JAK inhibitors in pregnancy are limited, and there may be concerns about effects on fetal development and the immune system. Women of childbearing potential are usually advised to use effective contraception during treatment and for a period after stopping the medicine, as recommended in the product information. If you are pregnant, planning to become pregnant, or think you might be pregnant while taking Jaknat 5, you should inform your doctor immediately to discuss the safest course of action.

The safety of Jaknat 5 during breastfeeding is not well established, and it is not known to what extent the active substance passes into human breast milk. Because of the potential for serious adverse reactions in a nursing infant, use during breastfeeding is generally not recommended unless your doctor decides that the benefit to the mother outweighs the possible risk to the child. Your doctor may advise you either to avoid breastfeeding while on Jaknat 5 or to consider an alternative treatment. Always discuss your breastfeeding plans with your healthcare provider before starting or continuing this medicine.

Jaknat 5 is not primarily known to impair the ability to drive or use machines in most patients. However, some people may experience side effects such as dizziness, fatigue, or headache, which could affect concentration and reaction time. Until you know how Jaknat 5 affects you, it is sensible to be cautious with activities that require full alertness, such as driving, operating heavy machinery, or working at heights. If you feel unusually tired, dizzy, or unwell after taking the medicine, avoid such activities and consult your doctor.

Moderate alcohol intake may be permissible for some patients on Jaknat 5, but it should be approached with caution, especially in those with existing liver problems or other risk factors. Both alcohol and JAK inhibitors can place additional strain on the liver, and excessive alcohol consumption may increase the risk of liver damage or worsen side effects such as dizziness or gastrointestinal upset. It is advisable to discuss your alcohol consumption honestly with your doctor, who can provide individualized guidance. Avoid binge drinking and seek medical advice if you notice symptoms suggestive of liver or general health problems.

You should not take Jaknat 5 if you are known to be allergic to its active ingredient or any of the excipients listed in the product leaflet. Inform your doctor about any previous allergic reactions to medicines, especially other JAK inhibitors or immunomodulatory drugs. Signs of a serious allergic reaction can include rash, itching, swelling of the face, lips, tongue, or throat, severe dizziness, or difficulty breathing. If any of these occur after taking Jaknat 5, seek emergency medical help immediately and do not take further doses until you have been evaluated. Your doctor may recommend an alternative treatment if you are at high risk of hypersensitivity.

Before and during treatment with Jaknat 5, your doctor will usually check for infections, perform blood tests to monitor blood counts, liver and kidney function, and may assess your cardiovascular and clotting risk. Inform your doctor if you have a history of tuberculosis, hepatitis, recurrent infections, blood clots, heart attack, stroke, cancer, or gastrointestinal perforation. Avoid live vaccines while on therapy and tell any healthcare professional treating you that you are taking a JAK inhibitor. Report symptoms such as persistent fever, weight loss, night sweats, shortness of breath, chest pain, leg swelling, severe abdominal pain, or unusual bruising without delay. Do not stop or restart Jaknat 5 without medical advice.

Jaknat 5MG Tablet 10's contains Tofacitinib 5 MG.

Jaknat 5MG Tablet 10's is listed at Rs. 294.85 on Medkart. Prices can change — check the product page for the current price and pack size.

The dose of Jaknat 5MG Tablet 10's depends on your condition, age, weight and other medicines you take, so it must be decided by your doctor. Follow the dose and duration on your prescription and do not change it on your own.

A generic medicine is one with the same active composition as the branded product — for Jaknat 5MG Tablet 10's that is Tofacitinib 5 MG. Medkart lists generic options by composition so you can compare. Ask your doctor or pharmacist before switching from Jaknat 5MG Tablet 10's.

Yes. Jaknat 5MG Tablet 10's requires a valid doctor's prescription.

Jaknat 5MG Tablet 10's is manufactured by Natco Pharma Limited.

Jaknat 5MG Tablet 10's is supplied as a tablet and is taken by the oral route.

Whether Jaknat 5MG Tablet 10's can be taken daily, and for how long, depends on your condition and must be decided by your doctor. Do not start, extend or repeat a course of Jaknat 5MG Tablet 10's on your own.

The timing of Jaknat 5MG Tablet 10's depends on the dose your doctor prescribes and on the other medicines you take. Follow the timing on your prescription or ask your pharmacist.

No. Jaknat 5MG Tablet 10's is a prescription medicine and should only be taken on a doctor's advice.

Store Jaknat 5MG Tablet 10's in its original pack, below 25°C unless the pack states otherwise, away from direct sunlight and moisture, and out of the reach of children. Do not use it after the expiry date on the pack.